bioRxivGenomicsPreprint
Recurrent mutations in topoisomerase 2a cause a novel mutator phenotype in human cancers
Abstract
Topoisomerases are essential for genome stability. Here, we link the p.K743N mutation in topoisomerase TOP2A to a previously undescribed mutator phenotype in human cancers. This phenotype primarily generates a distinctive pattern of duplications of 2 to 4 base pairs and deletions of 6 to 8 base pairs, which we call ID_TOP2A. All tumors carrying the TOP2A p.K743N mutation showed ID_TOP2A, which was absent in all of 12,269 other tumors. We also report evidence of structural variation associated with TOP2A p.K743N. All tumors with ID_TOP2A mutagenesis had several indels in known cancer genes, including frameshift mutations in PTEN and TP53 and an in-frame activating mutation in BRAF. Thus, ID_TOP2A mutagenesis almost certainly contributed to tumorigenesis in these tumors. This is the first report of topoisomerase-associated mutagenesis in human cancers, and sheds further light on TOP2As role in genome maintenance. We also postulate that tumors showing ID_TOP2A mutagenesis might be especially sensitive to topoisomerase inhibitors.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Topoisomerase IIb binding underlies frequently mutated elements in cancer genomes
Liis Uusküla-Reimand, Christian A. Lee, … Jüri Reimand·Nature CommunicationsPeer-reviewed·Nov 21, 2025
- Trapped Topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast
Nicole Stantial, Anna T. Rogojina, … John L. Nitiss·Proceedings of the National Academy of SciencesPeer-reviewed·Oct 12, 2020
- A multi-species toolkit of TOP2 hypercleavage mutants for studying topoisomerase II-mediated DNA damage
David Ontoso, Monika Mehta, … Scott Keeney·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 1, 2026
- Systematic Generation of Mutations at Topoisomerase II Cleavage Sites Enables Cancer Adaptation to Doxorubicin Therapy
Valid Gahramanov, Anjana Edathil Kadangodan, … Michael Y. Sherman·bioRxiv·Aug 21, 2026
- Genome-scale genetic interactions position the Mitotic Exit Network as a major antagonist of transient Topoisomerase II deficiency.
Cristina Ramos-Pérez, Jessel Ayra‐Plasencia, … Félix Machín·G3 Genes Genomes GeneticsPeer-reviewed·Aug 24, 2017
- KMT2C deficiency promotes APOBEC mutagenesis and genomic instability in multiple cancers